Braingate -TM- System Progress Detailed at American Spinal Injury Association Annual Meeting; M*Power -TM- Controller Program Outlined.

FOXBOROUGH, Mass. -- Progress of the ongoing initial clinical trial of the BrainGate(TM) Neural Interface System, under development by Cyberkinetics Neurotechnology Systems, Inc. (OTCBB - CYKN), was detailed today in a presentation to the Annual Meeting of the American Spinal Injury Association (ASIA). This first formal podium presentation of BrainGate trial results was made by Dr. Steve Williams, Assistant Professor of Rehabilitation Medicine at Boston University School of Medicine and Chair of the Department of Rehabilitation Medicine at Boston Medical Center. Dr. Williams is a clinical advisor to Cyberkinetics.

Dr. Williams presented a description of the BrainGate M*Power(TM) Controller, a next generation, standardized interface which is under development and initial testing to replace the initial prototype controller which has been used in the BrainGate trial until now. The M*Power Controller is designed to allow a BrainGate system patient to control a standard wireless computer device. The new interface is also intended to be easier to use for patients and their families, so that they can access the capabilities of the system on a routine basis without reliance on a technician. These two closely linked efforts are intended to yield a BrainGate system that allows patients significant control over their environment, the ability to readily perform numerous daily activities that are currently beyond their reach, and vastly enhanced communications opportunities.

As an example, use of the M*Power Controller as an interface to control, by thought alone, a hybrid cell phone/computer such as an iPAQ would allow patients to perform a range of tasks, including:

--Making and receiving telephone calls

--Controlling remote devices

--Accessing the internet

--Communicating via e-mail.

Dr. Williams also reported on clinical results achieved to date in the BrainGate trial. As previously reported, results from the first patient provide clear demonstration that:

--The BrainGate system is able to detect, transmit and analyze the firing of individual neurons in the patient's motor cortex;

--The patient is able to modulate these neurons by imagining arm and hand movement;

--The BrainGate system has been able to translate these signals into a cursor controller;

--Using this controller, the patient has shown the ability to perform activities of daily living:

--Control a computer interface (desktop)

--Control remote devices (TV)

--Control a prosthetic limb in an example of limb movement.

Results from the second patient, who was implanted recently, are not yet available.

Finally, Dr. Williams discussed how the type of cortical control demonstrated by the BrainGate system can be applied to the problem of limb movement, and provided the first public discussion of Cyberkinetics' plans to collaborate with various groups involved in the advanced study of thought-controlled limb movement.

"We are extremely pleased and excited by the progress that Dr. Williams reported," said Timothy R. Surgenor, President and CEO of Cyberkinetics Neurotechnology Systems, Inc. "We've shown initial proof of concept that the BrainGate system works, and that control of a computer by thought alone is a clinical reality. We are now actively engaged in the design and execution of next generation interfaces which are easier to control on a daily basis."

"Based on the results that Dr. Williams reported," Surgenor said, "We are moving as quickly as we can to enter into partnerships with researchers to work toward the goal of BrainGate system control of limb movement; this is an essential step in maximizing functional restoration for spinal cord injury patients and others with severe neurological impairments. Our goal is to use research sessions in the current pilot trial to simulate the requirements of useful control of limb movement using the BrainGate device."

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, a leader in brain-machine interface technology, is developing products to treat nervous system diseases and disorders by bringing together advances in neuroscience, computer science and engineering. Cyberkinetics' products are based on over ten years of technology development and cutting-edge neuroscience research at leading academic institutions such as Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. Cyberkinetics is publicly traded on the Over the Counter Bulletin Board under the ticker symbol CYKN. The Company is headquartered in Foxborough, Massachusetts and conducts engineering and research in Salt Lake City, Utah.

Cyberkinetics' flagship product, the BrainGate(TM) Neural Interface System, is designed to give severely paralyzed individuals a long-term, direct brain-computer interface for the purpose of communication and control of a computer and other devices. Patients are currently being enrolled into a pilot clinical trial to test the BrainGate(TM) System's safety and effectiveness.

Cyberkinetics has received FDA clearance to market the NeuroPort(TM) System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity. The NeuroPort System can contribute to the diagnosis and treatment of neurological conditions in patients who have undergone craniotomy by providing neurologists and neurosurgeons a new resource to detect, transmit and analyze neural activity.

Additional information is available at www.cyberkineticsinc.com.

Forward Looking Safe Harbor Statement

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.